This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

开始日期2029-03-01

申办/合作机构

Womack Army Medical Center

[+1]

NCT06366672 / Not yet recruiting早期临床1期IIT

Evaluating the Durability of the Human Immune Response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine

This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.

开始日期2024-06-01

申办/合作机构

Washington University School of Medicine

NCT05745987 / Not yet recruiting临床4期IIT

SMART (Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster Randomized Controlled Trial)

A cluster randomized controlled trial to determine if smallpox vaccine reduces secondary cases and symptom severity in persons exposed to mpox.

开始日期2023-07-01

申办/合作机构

McMaster University

100 项与天花疫苗(Bavarian Nordic A/S) 相关的临床结果

登录后查看更多信息

100 项与天花疫苗(Bavarian Nordic A/S) 相关的转化医学

登录后查看更多信息

100 项与天花疫苗(Bavarian Nordic A/S) 相关的专利（医药）

登录后查看更多信息

1,427

项与天花疫苗(Bavarian Nordic A/S) 相关的文献（医药）

2108-11-15·Psychiatria Danubina4区 · 医学

NON-SUICIDAL SELF-INJURY AMONG UNIVERSITY STUDENTS IN TURKEY: THE EFFECT OF GENDER AND CHILDHOOD ABUSE

4区 · 医学

Article

作者: Idig-Camuroglu, Meltem ; Gölge, Z Belma

BACKGROUND:

The purpose of this study was to explore the effect of gender and childhood abuse on non-suicidal self-injurious (NSSI) behaviors among university students in Turkey.

SUBJECTS AND METHODS:

In this study convenience sampling technique was used, the sample consisted of 1000 young adults who were from the eight universities in two big cities; Istanbul and Ankara. Besides with demographic questionnaire, Inventory of Statements about Self-Injury and Childhood Trauma Questionnaire were used.

RESULTS:

The prevalence of NSSI was 28.5% and the most prevalent three self-injurious behaviors were wound picking, banging/hitting and pinching self. There was not a gender difference in NSSI behavior frequency but in the type of behavior; males had significantly higher percentages of hitting and burning behavior. Examining the intrapsychic and interpersonal functions of NSSI, "affect regulation" and "toughness" functions were the most used ones among the participants. In terms of gender differences, "revenge" function was used by females more than males. Self-injurers had higher childhood abuse scores on sexual, physical, and emotional abuse and neglect subscales than non self-injurers, and males were significantly more abused than females.

CONCLUSIONS:

Accepting childhood abuse as an important predictor of NSSI behavior, screening and assessment of abused children and adolescents can help to prevent the onset of the behavior.

2024-12-31·Expert Review of Vaccines

Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials

Review

作者: Miao, Mingsan ; Qin, Changjiang ; Wang, Chaoyang ; Zhang, Liang ; Yin, Juntao

BACKGROUND:

This review aimed to systematically evaluate the immunogenicity and safety of the candidate Ebola virus vaccine (EVV).

METHODS:

We searched five databases for randomized controlled trials (RCTs) evaluating the effects of EVV on healthy adults. The primary outcomes were relative risk (RR) of sero-conversion or sero-response of EVV in healthy adults between the groups that received EVV and the controls.

RESULTS:

Twenty-nine RCTs (n = 23573) were included. There was a significant difference in RR of sero-conversion of EVV (RR 13.18; 95% CI 11.28-15.41; I² = 33%; P < 0.01) between the two groups. There was a significant difference in RR of adverse events (AEs) of EVV (RR 1.49; 95% CI 1.27-1.74; I² = 88%; P < 0.01), although no difference in RR of serious AE (SAE) between the two groups. Subgroup analysis showed that there was no significant difference in RR of AEs for DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 vaccines, compared with controls.

CONCLUSIONS:

The DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 vaccines are likely to be safe and immunogenic, tending to support the vaccination against Ebola disease. These findings should provide much-needed evidence for public health policy makers to develop preventive measures based on disease prevalence features and socio-economic conditions.

2024-02-01·eClinicalMedicine

Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study

Article

作者: Rosati, Silvia ; Corso, Rita ; Giancola, Maria Letizia ; Camici, Marta ; Cannone, Fabio ; Nappo, Alessandra ; Sarmati, Loredana ; Mazzotta, Stefania ; Scanzano, Pietro ; Matusali, Giulia ; Caterini, Luciano ; Siddu, Andrea ; Plazzi, Maria Maddalena ; Cimaglia, Claudia ; Lapa, Daniele ; Junea, Angela ; Notari, Stefania ; Grassi, Germana ; Preziosi, Gianni ; Faccendini, Paolo ; D'Ettorre, Gabriella ; Pinnetti, Carmela ; Gagliardini, Roberta ; Tartaglia, Eleonora ; Possi, Adriano ; Maggi, Fabrizio ; Natalini, Giorgia ; Lepri, Alessandro Cozzi ; Girardi, Enrico ; Nicastri, Emanuele ; Bettini, Aurora ; Agrati, Chiara ; Lamonaca, Alessandra ; Cruciani, Stefania ; Fontana, Carla ; Passacantilli, Sara ; Gili, Simona ; Rubino, Marika ; Caputi, Priscilla ; Faraglia, Francesca ; Del Duca, Giulia ; Meschi, Silvia ; De Ponte, Chiara ; Vescovo, Maurizio ; Mondillo, Vanessa ; Masone, Erminia ; Lanini, Simone ; Mazzotta, Valentina ; Vaia, Francesco ; Piselli, Pierluca ; Cimini, Eleonora ; Di Giambenedetto, Simona ; Latini, Alessandra ; Stingone, Christof ; Montagnari, Giulia ; Paulicelli, Jessica ; Antinori, Andrea ; Coppola, Luigi ; Barca, Alessandra ; Faticoni, Augusto ; Marocco, Raffaella ; Tamburrini, Enrica ; Vita, Serena ; Marchili, Mauro ; Aguglia, Camilla ; Mondi, Annalisa ; Marani, Alessandra ; Vergori, Alessandra ; Fusto, Marisa ; Anzalone, Enza ; Farinacci, Damiano ; Kontogiannis, Dimitra ; Lichtner, Miriam ; Iannella, Maria Rosaria ; Scorzolini, Laura ; Giannico, Giuseppina ; De Marco, Nicola ; Cristofanelli, Flavia ; Oliva, Alessandra ; Gallì, Paola ; Colavita, Francesca ; Tomassi, Virginia ; Gebremeskel, Saba ; Parisi, Alfredo ; Mastrorosa, Ilaria ; Casetti, Rita ; Ridolfi, Marco ; Mastroianni, Claudio

Background:

Pre-exposure vaccination with MVA-BN has been widely used against mpox to contain the 2022 outbreak. Many countries have defined prioritized strategies, administering a single dose to those historically vaccinated for smallpox, to achieve quickly adequate coverage in front of low supplies. Using epidemiological models, real-life effectiveness was estimated at approximately 36%-86%, but no clinical trials were performed. Few data on MVA-BN immunogenicity are currently available, and there are no established correlates of protection. Immunological response in PLWH in the context of the 2022 outbreak was also poorly described.

Methods:

Blood samples were collected from participants eligible for pre-exposure MVA-BN vaccination before (T1) receiving a full course of vaccine (single-dose for vaccine-experienced or smallpox-primed and two-dose for smallpox vaccine-naïve or smallpox non-primed) and one month after the last dose (T2 and T3, respectively). MPXV-specific IgGs were measured by in-house immunofluorescence assay, using 1:20 as screening dilution, MPXV-specific nAbs by 50% plaque reduction neutralization test (PRNT₅₀, starting dilution 1:10), and IFN-γ-producing specific T cells to MVA-BN vaccine, by ELISpot assay. Paired or unpaired t-test and Wilcoxon or Mann-Whitney test were used to analyse IgG and nAbs, and T-cell response, as appropriate. The probability of IgG and nAb response in vaccine-experienced vs. vaccine-naïve was estimated in participants not reactive at T1. The McNemar test was used to evaluate vaccination's effect on humoral response both overall and by smallpox vaccination history. In participants who were not reactive at T1, the proportion of becoming responders one month after full-cycle completion by exposure groups was compared by logistic regression and then analysed by HIV status strata (interaction test). The response was also examined in continuous, and the Average Treatment Effect (ATE) of the difference from baseline to schedule completion according to previous smallpox vaccination was estimated after weighting for HIV using a linear regression model. Self-reports of adverse effects following immunization (AEFIs) were prospectively collected after the first MVA-BN dose (T1). Systemic (S-AEFIs: fatigue, myalgia, headache, GI effects, chills) and local (L-AEFIs: redness, swelling, pain) AEFIs were graded as absent (grade 0), mild (1), moderate (2), or severe (3). The maximum level of severity for S-AEFIs and L-AEFIs ever experienced over the 30 days post-dose by vaccination exposure groups were analysed using a univariable multinomial logistic regression model and after adjusting for HIV status; for each of the symptoms, we also compared the mean duration by exposure group using an unpaired t-test.

Findings:

Among the 164 participants included, 90 (54.8%) were smallpox vaccine-experienced. Median age was 49 years (IQR 41-55). Among the 76 (46%) PLWH, 76% had a CD4 count >500 cells/μL. There was evidence that both the IgG and nAbs titers increased after administration of the MVA-BN vaccine. However, there was no evidence for a difference in the potential mean change in humoral response from baseline to the completion of a full cycle when comparing primed vs. non-primed participants. Similarly, there was no evidence for a difference in the seroconversion rate after full cycle vaccination in the subset of participants not reactive for nAbs at T1 (p = 1.00 by Fisher's exact test). In this same analysis and for the nAbs outcome, there was some evidence of negative effect modification by HIV (interaction p-value = 0.17) as primed people living with HIV (PLWH) showed a lower probability of seroconversion vs. non-primed, and the opposite was seen in PLWoH. When evaluating the response in continuous, we observed an increase in T-cell response after MVA-BN vaccination in both primed and non-primed. There was evidence for a larger increase when using the 2-dose vs. one-dose strategy with a mean difference of -2.01 log₂ (p ≤ 0.0001), after controlling for HIV. No evidence for a difference in the risk of developing any AEFIs of any grade were observed by exposure group, except for the lower risk of grade 2 (moderate) fatigue, induration and local pain which was lower in primed vs. non-primed [OR 0.26 (0.08-0.92), p = 0.037; OR 0.30 (0.10-0.88), p = 0.029 and OR 0.19 (0.05-0.73), p = 0.015, respectively]. No evidence for a difference in symptom duration was also detected between the groups.

Interpretation:

The evaluation of the humoral and cellular response one month after the completion of the vaccination cycle suggested that MVA-BN is immunogenic and that the administration of a two-dose schedule is preferable regardless of the previous smallpox vaccination history, especially in PLWH, to maximize nAbs response. MVA-BN was safe as well tolerated, with grade 2 reactogenicity higher after the first administration in vaccine-naïve than in vaccine-experienced individuals, but with no evidence for a difference in the duration of these adverse effects. Further studies are needed to evaluate the long-term duration of immunity and to establish specific correlates of protection.

Funding:

The study was supported by the National Institute for Infectious Disease Lazzaro Spallanzani IRCCS "Advanced grant 5 × 1000, 2021" and by the Italian Ministry of Health "Ricerca Corrente Linea 2".

263

项与天花疫苗(Bavarian Nordic A/S) 相关的新闻（医药）

2024-05-02

·生物制品圈

王健伟、郭斐团队揭示中国人群针对天花疫苗的既存免疫力及对猴痘病毒的交叉保护性作用

2024年1月19日，王健伟、郭斐研究团队在国际传染病权威杂志Emerg Infect Dis《新发传染病》在线发表题为“Residual Immunity from Smallpox Vaccination and Possible Protection from Mpox，China”的研究论文。作为天花疫苗，痘苗病毒天坛株（VTT）在中国消灭天花的卫生运动中发挥了重要作用。1980年世卫组织宣布根除天花后，国内停止了常规的天花疫苗接种。2022年9月中国报告了第一例猴痘输入性病例，为系统评价中国人群体内的针对痘苗病毒的既存免疫力及对猴痘病毒的交叉保护作用，本研究采集了来自于北京、山西省、黑龙江省、湖北省以及深圳的1070例健康人外周血样本，进行针对VTT的抗体、记忆性B细胞和记忆性T细胞免疫学分析。在参与研究的人群中，478例出生于1930–1979年，592例出生于1980–2008年。研究发现，在1980年以前出生的人群中，28.7%的人检测到针对VTT的中和抗体，71.4%的人检测到记忆B细胞反应，65.7%的人检测到记忆T细胞反应。而1980后出生人群，几乎检测不到针对VTT 的抗体、记忆性B细胞和记忆性T细胞免疫反应。上述数据表明，1980年前出生的人群针对VTT的中和抗体水平在衰减，但大多数人仍存在针对VTT的记忆性B细胞和记忆性T细胞免疫反应，由于VTT与猴痘病毒存在较高的序列同源性，猴痘病毒再暴露或疫苗接种后，1980年前出生人群的免疫记忆可以迅速活化并产生保护性免疫反应，但1980年后出生的人群普遍缺乏针对猴痘病毒的免疫力。上述研究为猴痘疫苗的接种策略提供重要的数据支持。图. 不同年龄组人群针对痘苗病毒天坛株的记忆性B细胞和记忆性T细胞免疫反应本研究得到国家自然科学基金（ 81930063、82241075、82271802、82072288、32200718）、国家自然科学基金创新研究群体科学基金（82221004）、国家重点研发计划（2022YFE0203100）、中国医学科学院医学与健康科技创新工程（2021-I2M-1-038、2021-I2M-1-047），中央高校基本科研业务费（3332021092）等项目的支持。我所王健伟教授、郭斐教授为论文共同通讯作者，博士后黄羽、郭丽研究员、博士生李雅楠、任丽丽研究员、博士生聂纪芹、许丰雯副研究员为本文的共同第一作者。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗

2024-05-01

·生物制药小编

10类疫苗特点

疫苗的发明极大地降低了相关疾病的发生率和死亡率，据统计每年约可避免600万人死亡。疫苗的首次登场在1796年，是由Edward Jenner开发的天花疫苗，解决了之前天花死亡率30%的问题。此后，疫苗产业发展迅速，多种技术各有所长。一、活体疫苗/减毒疫苗含有弱化形式的细菌，只诱发免疫反应，不会导致疾病。第一款活体疫苗就是天花疫苗。优点：不需要佐剂；产生细胞/体液免疫；单剂量足以提供免疫反应。缺点：有毒性恢复风险；免疫功能低下患者有使用风险；储存条件要求严格，储存时间短。二、灭活疫苗使用化学/物理方式灭活病原体，使其丧失致病能力。第一款灭活疫苗是霍乱疫苗。优点：不会恢复毒性；成本降低；免疫功能低患者可用。缺点：需要佐剂；需要使用多剂量；研发繁琐，病原体培养要求高。三、亚单位疫苗具有抗原特异性的病原体片段（如蛋白质、多肽、糖），即可诱发免疫反应的抗原。第一款亚单位疫苗是乙肝疫苗。优点：不包含完整病原体，安全性较高，副作用风险较小，不会引起疾病状态；可提供精准的免疫靶点；不需冷藏，易于运输和储存。缺点：特定抗原分离困难；成分单一，免疫反应较传统疫苗弱；需要佐剂增强功效。四、类毒素来自细菌分泌的毒素，经理化方式处理后只保留了诱发抗体形成特性。世界上第一款类毒素疫苗是白喉类毒素疫苗。优点：安全性很高稳定、持久；不易受温度、湿度、光影响；没有reversion情况缺点：需要增强剂来维持免疫反应；制备成本高；注射部位易发生不良反应五、多糖-蛋白结合疫苗将抗原蛋白和多糖结合形成，以蛋白为载体的细菌多糖类疫苗。增加了抗原表面积，提高多糖的免疫原性。第一款多糖-蛋白结合疫苗是Ⅰb型流感嗜血杆菌（Hib）结合疫苗。优点：可形成免疫记忆；可预防无症状疾病；安全性、耐受性好；婴幼儿免疫效果好。缺点：制备成本较高；不能针对非囊膜变体；难针对所有细菌血清型。六、病毒样颗粒（VLP）疫苗源自病毒本身，由其中单一或多结构蛋白自行装配形成，可模仿病毒大小、构象，与病毒十分相似而易于被免疫系统识别。不包含病毒遗传物质，不会引起疾病。第一款VLP疫苗是乙肝疫苗。优点：安全性高，无病毒基因组，可防止病毒灭活不完全的潜在致病性；不需要佐剂；诱发强烈B细胞反应；表达系统多样；稳定性高。缺点：纯化要求高；制备工艺复杂；生产成本高；条件变化时稳定性变差。七、病毒载体疫苗将减毒活病毒作为载体，替换部分基因后制备而成。优点：基因转导效率高；靶向性高；可诱导细胞和体液免疫；基因表达持续久。缺点：可能诱发抗载体免疫反应；未接种前可能已形成针对载体的免疫反应；规模化生产困难。八、mRNA疫苗将mRNA引入细胞，产生蛋白后促进产生抗体的免疫反应。获得2023年的诺贝尔生理学奖，对于新冠的贡献非常大，但可能因此光环下隐藏了一些问题。优点：无需输送系统；制备时间短。缺点：引发炎症副作用；稳定性可能较差；（推荐阅读：mRNA）九、DNA疫苗将免疫原基因插入质粒形成，接受转染的宿主细胞表达蛋白质并产生针对该蛋白的免疫反应。目前只在实验阶段，无成品。优点：稳定性高；易于开发、生产；免疫反应集中；免疫反应持久；可提供体液和细胞免疫；缺点：免疫原性较差；只引起针对蛋白质抗原的的免疫反应；可能发生抗生素耐药性；可能产生抗DNA抗体，有自免疾病发生风险。十、DC疫苗属于肿瘤疫苗，提取体内DC并暴露在肿瘤肽或肿瘤mRNA条件下，然后重新移植回体内。优点：免疫原性高；诱导高肿瘤免疫反应；具有免疫记忆。缺点：靶抗原选择困难；生产技术复杂，成本高。（推荐阅读：DC细胞及DC疫苗研究简史）

疫苗信使RNA

2024-04-29

·GlobeNewswire-Health Care

Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve

COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic reserve within the European Union (EU) in 2025. This third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to rescEU stockpiles across Europe and will help to expand the EU’s capability to respond to future biological threats and emergencies by enabling rapid deployment of medical countermeasures to its member states. Paul Chaplin, President & CEO of Bavarian Nordic, said: “Public health crises in recent years have demonstrated the need for building a robust infrastructure across EU nations for deploying vaccines in emergencies. We applaud the rescEU initiative, which aims to reinforce the EU’s ability to respond to future health crises and through incremental orders for our smallpox vaccine will further strengthen the biological preparedness across the region. We are pleased to expand this collaboration, as we further increase our commitments to supplying smallpox vaccines to a growing customer base, while also adding to our base of secured contracts for 2025.” About the smallpox vaccineMVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed under the brand names JYNNEOS®, IMVANEX® and IMVAMUNE®) is a non-replicating smallpox and mpox vaccine. The vaccine is approved by the FDA, EC, Health Canada, MHRA and Swissmedic and has also obtained emergency use authorization in other territories for use during the mpox outbreak. The vaccine was originally developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. About rescEURescEU is part of the EU Civil Protection Mechanism, established by the European Commission as a safety net to protect citizens from disasters and manage emerging risks. It includes, among others, reserves of medical countermeasures which can be deployed in chemical, biological, radiological, and nuclear (CBRN) emergencies. The EU sanitary stockpiles are built in cooperation with the Health Emergency Preparedness and Response Authority (HERA) created by the EU at the end of 2021 following the COVID-19 crisis. Read more:https://civil-protection-humanitarian-aid.ec.europa.eu/what/civil-protection/resceu_en https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera_en About Bavarian NordicBavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. ContactsEurope: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, graham@paddockcircle.com, Tel: +1 781 686 9600 Company Announcement no. 10 / 2024 Attachment 2024-10-en

疫苗上市批准加速审批

100 项与天花疫苗(Bavarian Nordic A/S) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	天花疫苗(Bavarian Nordic A/S)	J07BX	DB15483

研发状态

适应症	最高研发状态	国家/地区	公司
猴痘	批准上市	列支敦士登更多	Bavarian Nordic A/S 更多
天花	批准上市	挪威更多	Bavarian Nordic A/S 更多
季节性过敏性鼻炎	无进展	德国更多	Bavarian Nordic A/S 更多
接种后牛痘	无进展	韩国更多	Bavarian Nordic A/S 更多
特应性皮炎	无进展	美国更多	Bavarian Nordic A/S 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05512949 (CTgov)	临床2期	猴痘	229	MVA-BN (2 x 10^7 ID MVA-BN)	鹹鏇窪憲鏇衊衊淵鹹夢(廠築艱獵網鹽鹽鏇構築) = 範襯壓顧齋醖構觸網廠衊鹽糧鬱鹽齋顧襯廠鏇 (夢糧廠簾選齋簾鏇壓淵, 遞積憲醖鬱齋顧餘窪襯 ~ 積廠鹹繭願蓋襯蓋鹹鏇) 更多	-	2024-01-09
				MVA-BN (1 x 10^7 ID MVA-BN)	鹹鏇窪憲鏇衊衊淵鹹夢(廠築艱獵網鹽鹽鏇構築) = 鏇餘簾淵蓋獵糧願齋憲衊鹽糧鬱鹽齋顧襯廠鏇 (夢糧廠簾選齋簾鏇壓淵, 鹽衊蓋膚鏇願糧簾鹽製 ~ 選構構艱壓鏇顧積醖襯) 更多
NCT03699124 (Pubmed) 人工标引	临床3期	-	1,129	MVA-BN	鏇衊鬱鏇顧廠膚選網積(艱築夢鹹鹹鏇淵範遞積) = 廠遞鹹遞選齋製壓願範齋簾齋艱築憲壓構築蓋 (餘壓築襯觸蓋鑰襯選蓋 ) 更多	积极	2022-11-29
NCT03699124 (CTgov)	临床3期	天花	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	築衊鹹鬱簾願蓋積壓壓(窪鹹願餘鑰鹽製壓鹹構) = 艱糧廠醖餘願獵艱膚膚餘憲製繭顧遞艱鬱製鬱 (簾簾齋廠艱夢鹽獵衊鹹, 鏇選鹹憲範鏇鏇網膚鏇 ~ 鏇艱壓鬱網憲顧鑰選鬱) 更多	-	2021-05-27
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	築衊鹹鬱簾願蓋積壓壓(窪鹹願餘鑰鹽製壓鹹構) = 鑰顧衊願觸鬱憲糧鏇淵餘憲製繭顧遞艱鬱製鬱 (簾簾齋廠艱夢鹽獵衊鹹, 醖築構糧艱網夢簾範製 ~ 獵願範顧繭鏇觸鑰網遞) 更多
NCT01668537 (CTgov)	临床2期	天花	651	LF (LF Formulation)	憲膚築鬱製築鹽襯廠鑰(鹹鹹構網顧積遞憲膚鑰) = 願選築餘願積築繭壓簾窪鏇襯選願顧廠廠鹹夢 (糧積顧鑰衊獵糧鬱顧醖, 夢鑰製鑰廠獵蓋製膚繭 ~ 蓋艱壓壓鏇餘製淵艱淵) 更多	-	2020-10-12
				MVA-BN (FD Formulation)	憲膚築鬱製築鹽襯廠鑰(鹹鹹構網顧積遞憲膚鑰) = 獵製膚範襯獵願觸壓範窪鏇襯選願顧廠廠鹹夢 (糧積顧鑰衊獵糧鬱顧醖, 獵獵構壓繭淵衊製鹽壓 ~ 齋網願顧觸範鹽糧鏇襯) 更多
NCT03472014 (CTgov)	临床4期	-	22	MVA-BN	獵鬱糧獵窪鏇遞廠鹽築(簾繭範糧壓願顧觸獵遞) = 簾廠齋壓鹹餘鬱簾製繭鬱壓夢網淵衊選夢襯鏇 (鹽築鑰獵構遞遞廠餘築, 鏇願鏇鏇齋簾鬱壓鹹鏇 ~ 壓構憲艱顧顧憲選願範) 更多	-	2020-08-19
NCT01913353 (Pubmed \| Br Dent J) 人工标引	临床3期	天花	433	modified vaccinia Ankara+ACAM2000	簾鑰選襯築築選廠製窪(鬱夢鏇淵構餘醖衊製膚): RO = 97.9 (95% CI, 96.6 ~ 98.3) 更多	优效	2019-11-14
				ACAM2000
NCT00686582 (CTgov)	临床2期	天花	304	IMVAMUNE (Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose)	繭鏇艱簾衊蓋願壓夢淵(遞構網鏇衊醖衊積顧蓋) = 範醖醖艱廠製醖網獵膚壓網餘蓋簾顧網觸糧積 (製鬱壓網餘廠積艱襯憲, 憲壓獵壓鑰衊齋齋鑰鑰 ~ 齋憲簾廠積蓋鹹繭膚鹽) 更多	-	2019-02-18
				IMVAMUNE (Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose)	繭鏇艱簾衊蓋願壓夢淵(遞構網鏇衊醖衊積顧蓋) = 廠鏇襯網製鬱膚艱壓壓壓網餘蓋簾顧網觸糧積 (製鬱壓網餘廠積艱襯憲, 築願窪築鏇憲廠襯艱窪 ~ 廠糧選餘鏇網憲齋醖簾) 更多
NCT00857493 (CTgov)	临床2期	天花	120	IMVAMUNE (Group 1)	餘淵構齋範繭壓衊壓築(網顧齋顧獵獵窪遞獵壓) = 觸願襯淵遞構艱餘願窪願淵鏇簾窪鏇鹽淵廠餘 (憲廠鑰鬱衊構製選醖遞, 餘膚製憲願襯糧鬱齋範 ~ 夢範淵鏇顧鏇憲獵壓觸) 更多	-	2019-01-10
				IMVAMUNE (Group 2)	餘淵構齋範繭壓衊壓築(網顧齋顧獵獵窪遞獵壓) = 襯醖淵觸淵憲鹽鬱衊願願淵鏇簾窪鏇鹽淵廠餘 (憲廠鑰鬱衊構製選醖遞, 襯餘夢顧願壓淵餘顧鹹 ~ 範膚夢製製廠鹹網願壓) 更多
NCT00316524 (CTgov)	临床2期	天花	745	MVA-BN® (IMVAMUNE) (GP 1: Two x 1x10E08 TCID, MVA-BN® s.c., Vaccinia Naive)	願鬱鹹簾廠艱遞艱憲糧(鏇繭鹽顧鬱網獵淵鏇構) = 餘廠製鹹鑰醖壓鹽夢餘廠夢鬱願構顧鬱繭積簾 (夢繭遞壓窪艱鏇遞顧壓, 蓋願網範繭選膚構壓願 ~ 選膚積願網齋蓋夢築鏇) 更多	-	2019-01-09
				Placebo+MVA-BN® (IMVAMUNE) (GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., Vaccinia Naive)	願鬱鹹簾廠艱遞艱憲糧(鏇繭鹽顧鬱網獵淵鏇構) = 膚獵窪窪壓網蓋襯製蓋廠夢鬱願構顧鬱繭積簾 (夢繭遞壓窪艱鏇遞顧壓, 鹹鏇淵憲選積願構夢衊 ~ 壓淵鑰艱鏇構範廠鏇襯) 更多
NCT00316602 (CTgov)	临床2期	特应性皮炎	632	IMVAMUNE (Healthy Participants)	衊鹹遞鏇襯鹹繭蓋醖範(選淵餘製構鬱繭繭簾齋) = 齋蓋淵糧醖遞鏇顧築繭鏇糧淵獵憲壓餘鹽鹽繭 (憲構顧憲壓齋鬱糧製構, 糧窪夢觸夢網鏇壓壓膚 ~ 選鏇鬱醖鬱獵鹽衊憲願) 更多	-	2019-01-09
				IMVAMUNE (Atopic Dermatitis Participants)	衊鹹遞鏇襯鹹繭蓋醖範(選淵餘製構鬱繭繭簾齋) = 夢鬱鬱鏇蓋簾鑰繭網簾鏇糧淵獵憲壓餘鹽鹽繭 (憲構顧憲壓齋鬱糧製構, 憲鬱製餘壓鹽淵膚淵觸 ~ 餘壓觸繭簾壓獵繭淵鬱) 更多